Back

Notification report


Full notification file


General information

Notification Number
B/DE/19/PEI3779

Member State to which the notification was sent
Germany

Date of acknowledgement from the Member State Competent Authority
12/06/2019

Title of the Project
Phase I study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors ACTengine® IMA202-101)

Proposed period of release:
01/10/2019 to 30/06/2023

Name of the Institute(s) or Company(ies)
Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15
72076 T├╝bingen
Germany;
Immatics US, Inc., 2130 W. Holcombe Blvd, LSP11.3000
Houston, TX 77030
USA;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
Other: mammals

Identity of the GMO:
The GMO is used as an investigational medicinal product (IMP) and consists of autologous patient-derived target-specific somatic CD3+ T cells expressing a TCR, which recognizes a specific cancer/germline antigen presented by HLA-A*02:01. The T cells have been transduced ex vivo with a third-generation self-inactivating (SIN) lentiviral vector that encodes for the specific T-cell receptor.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HumanHomoSapiens---

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
27/12/2019 00:00:00
Remarks: